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Introduction
1INTRODUCTION
Urticaria is a distressing dermatosis of skin characterized by
transient erythematous edematous weals which are very itchy.
          Urticaria, commonly called 'hives,' has a long and rich history in
documented medicine dating back to the 10th century B.C1. Chronic
idiopathic urticaria (CIU) is defined as wide spread, short lived (< 24 h)
weals occurring daily or almost daily for at least 6 weeks, with no obvious
cause. Activation of cutaneous mast cells liberates various mediators
predominantly histamine which induces increased permeability of
capillaries and venules which in turn produces uriticaria.
          It is now recognized that approximately 30-40% of patients with
CIU have histamine-releasing autoantibodies directed against either the
high-affinity IgE receptor, or less frequently, IgE. This subset of patients
are categorized as having chronic autoimmune urticaria. The presence of
autoantibodies may be important clinically in severely affected, treatment-
resistant patients, where immunomodulatory treatments may be helpful2.
          The ASST (Autologous Serum Skin Test) is a simple invivo
screening test for detecting patients with autoimmunity3. It has a sensitivity
of 70% and a specificity of 80%. A positive test is suggestive but not
diagnostic of an autoimmune basis. Confirmation is needed by invitro
2testing of the patient's serum for the anti-Fc€RI? or the anti-IgE auto
antibodies. Basophil histamine release assay is the gold standard for
detecting functional autoantibodies. However, it is available only at a few
research centers and cannot be performed as a routine4. CIU is extremely
disabling in its severe form and can be difficult to treat. Autoimmune
urticaria patients with severe disease are at times refractory to treatment
with conventional antihistamines and need immunomodulators.
Autologous Serum Therapy (AST), a modified form of autologous whole
blood therapy, has been found to be fairly effective in chronic urticaria5.
Review of
literature
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History
Earliest description of the disease is found in “The Yellow
Emperor’s Inner Classic”, Huang Di Nei Jing written between 1000-200
BC6.  Hippocrates described the elevated itchy skin lesions caused by
stings of nettles and mosquitoes and named it as “Knidosis” after the
Greek word for nettle (knido). The word urticaria was first introduced in
1769 by William Cullen in his book “Synopsia Nosalogiae Methodica"7.
Terms like 'Uredo,' 'essera' (Arabic for elevation) and ‘urticatio’ (derived
from the Latin urere; to burn) have all been used previously8 . In 1986
Grattan et al noted that injection of autologous serum intradermally elicited
an immediate type of weal and flare reaction indicative of circulating mast
cell activating factors9. In 1993, hide et al reported the presence of
functional auto antibodies against high affinity receptor of IgE, Fc€RI?
causing histamine release in a subset of chronic urticaria patients10.
Epidemiology
          Urticaria is a worldwide disease and may present at any age. There is
no racial variance in the incidence. In one study point prevalence of 0.1%
is noted. The lifetime occurrence of urticaria in the general population
ranges from 1% to 5%11. Among chronic idiopathic urticaria patients,
4around 40-60% are found to have chronic autoimmune urticartia12.
Classification
Urticaria is broadly classified into:
Ordinary Urticaria
          Acute
          Episodic (acute and chronic intermittent)
          Chronic
Physical
           Dermographism
           Delayed pressure urticaria
           Cholinergic urticaria
           Cold urticaria
           Solar urticaria
           Aquagenic urticaria
           Heat urticaria
Vibratory angio odema
Urticarial vasculitis
Contact urticaria
Angioedema without weals
Other syndromes resembling urticaria or angioedema or with
urticaria as a component12.
5Acute and chronic urticaria are classified based on the time duration.
When symptoms are present for less than 6 weeks duration it is called
acute urticaria. If it appears almost daily, continuously for 6 or more weeks
it is termed as chronic urticaria12.
Chronic autoimmune Urticaria
Sera  of  approximately  60%  of  patients  with  chronic  ordinary
urticaria have shown to cause a weal when injected intradermally into
patients own skin. This indicates presence of circulating autoantibodies in
the blood. This group of patients are categorized as having chronic
autoimmune urticaria 3,5,12.
Genetics
            Hereditary angiodema, Muckle wells syndrome and few rare types
of physical urticaria are inherited as autosomal dominant traits. HLA DR4
and HLA DR8 are associated with chronic autoimmune urticaria13.
Causes of urticaria
1. Autoimmunity
Before the detection of functional autoantibodies which release
histamine from mast cells, majority of chronic urticaria patients were
categorized as having chronic idiopathic urticaria. These antibodies denote
6the presence of autoimmune etiology in an important subset of patients,
now classified as chronic autoimmune urticaria12.
Evidence for the presence of autoimmune etiology has been
concluded based on various investigations:
1. Occurrence of weal and flare on intradermal injection with patient’s
own serum9.
2. Serum and purified IgG derived from this subset of patients was able
to release histamine from mast cells and basophils in invitro tests.
3. The plasma level of these antibodies detected using ELISA,
Immunoblot assays varied in proportion with the disease activity14.
4. Clinical remission has occurred in patients following plasmapheresis
to remove these autoantibodies15.
2. ALLERGIC ETIOLOGY
Allergic reactions are only rarely responsible for chronic
urticaria16,17. It is an IgE mediated reaction. It occurs in an already
sensitized individual where preformed specific IgE are bound to the mast
cells. On repeated exposure, the allergen interacts with the IgE on mast
cells to release mediators. It occurs within minutes and not longer than 60
minutes12. The offending substance is easily recognized by the patient and
7avoided. Various drugs, food, injection and implants can be a potential
allergen.
3. NON ALLERGIC:
Direct mast cell liberators:
Substances like morphine, codeine, atracurium and antibiotics, such
as polymyxin and vancomycin can liberate histamine from mast cells
directly. It is not immunologically mediated and previous sensitization is
not required. It may occur after first exposure12.
Pseudo allergic reactions:
Drugs like aspirin and other non steroidal anti inflammatory drugs
cause urticaria by inhibiting cyclooxygenase pathway and  increased
diversion to lipooxygenase pathway resulting in increased production of
proinflammatory mediators like LTC4, LTD4, LTE4. It also reduces
PGE2 which is an inhibitor of immunological mast cell degranulation.
Pseudoallergic reactions is not substance specific and are related to the
dose of the offending substance18.
4. Drugs
Many drugs cause urticaria through allergic or non allergic
mechanisms19, 20.  Penicillins, cephalosporins, sulfonamides and
8tetracyclines are some examples of drug  induced urticaria. Drug which is
taken for a long time is unlikely to cause urticaria. On the contrary even a
small quantity of penicillin present in the dairy products may produce
severe urticaria in a sensitive person21.
5. Infections
Infections may produce either acute or chronic urticaria. Hepatitis B
viral infection, streptococcal throat infection, campylobacter jejuni and non
specific viral infections are few examples which can produce acute
urticaria. Bacterial infections of the dental, throat, respiratory, urinary
tracts, gall bladder and Helicobacter pylori rarely may be responsible for
chronic urticaria22, 23.
6. Infestations
           Gastro-intestinal parasites like Ankylostoma, Strongyloides,
Echinococcus and Toxacara canis can cause urticaria. However this has
become a rare cause as shown in recent Indian studies24.Ancylostoma and
Strongyloides worms migration can cause linear weals12. Toxacara canis
antibodies have been found to be associated with chronic urticaria, but a
causal relationship is not proven25.
97. Inhalants
Various substances like grass, pollens, mould, spores, animal
danders, and house dust may cause acute or chronic urticaria with or
without respiratory symptoms26.
8. Ingestion
Various food and food additives can cause both acute and chronic
urticaria. They cause urticaria by vasoactive amines present in them
(cheese, tomatoes, fish, meat, pineapples and avocados) or by the presence
of histamine releasing substances (strawberries).  Fish, milk, peanut, beans,
potato, rice, carrot and drumstick are responsible for acute urticaria
mediated through IgE dependant mechanism27. The reaction can occur in a
few minutes to many hours. Food additives like tartrazine, dyes like sunset
yellow, food preservatives like benzoate preservatives, antioxidants like
butylated hydroxytoluene and dyes used in medicinal products can all
cause urticaria. Among the alcoholic beverages, red wine which contains
vasoactive amines like histamine and white wine treated with sulphite may
cause urticaria in some28.
9. Insect bites
            Bite of insects like mosquitoes and bed bugs can cause chronic and
recurrent urticaria. Wasp or bee stings may produce severe acute urticaria
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or anaphylaxis through allergic mechanism which may be life
threatening29.
10. Implant
           Dental prosthesis, dental amalgams and metal pins used in
orthopaedics practice may rarely cause urticaria30.
11. Others
         Urticaria may occur in pregnancy and premenstrual exacerbation can
occur. Predominant premenstrual occurrence is linked to the sensitivity to
progesterone or estrogen on an autoimmune basis31. Psychological stress
can flare up urticaria32. Depression and anxiety were frequently found in
chronic urticaria patients. Depression has been found to reduce the
threshold for pruritus33.
            It is still not possible to identify the cause of urticaria in around
50% of patients. These patients are categorized as having chronic
idiopathic urticaria12.
Other aggravating factors include upper respiratory tract infections,
pressure, overheating, alcohol and viral infections.
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PATHOGENESIS
Mast cell is the principal effector cell of urticaria12. Degranulation of
mast cells can occur following immunological or non immunological
stimuli.
Immunological stimuli are seen in autoimmune and allergen
mediated urticaria. Fc€RI? are high affinity IgE receptors expressed on
mast  cells.  The  constant  region  domain  of  IgE,  CH3,  is  the  major  site  of
interaction with the IgE receptor on mast cells. When allergen binds to this
IgE receptor complex on mast cell, or when cross linking of adjacent
Fc€RI? occurs, there is activation and phosphorylation of protein tyrosine
kinase and phospholipase C. This induces the production of second
messengers like IP3 and DAG. IP3 increases intracellular calcium which
promotes the assembly of microtubules and the contraction of
microfilaments, both of which cause movement of granules to the plasma
membrane. Fusion of the granules with plasma membrane occurs with the
help of SNARE protein resulting in degranulation by exocytosis34.
Non-immunologic stimuli such as opioids, C5a anaphylotoxin, stem
cell factor as well as neuropeptides such as substance P can cause
degranulation via direct stimulation. These stimuli initiate calcium and
energy dependent steps that cause storage granules to fuse with the cell
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membrane and externalize their contents, which include preformed and
newly synthesized mediators of inflammation. Fc€RI? stimulation also
leads to upregulation of the synthesis and secretion of proinflammatory
mediators35.
Non mast cell dependent urticaria occur in C1 esterase inhibitor
deficiency (due to increased bradykinin) and in urticaria due to use of
angiotensin converting enzyme inhibitors (inhibition of breakdown of
bradykinin by angiotensin converting enzyme) 12.
Mast cell degranulation initiates the inflammatory process. The
recruitment of inflammatory cells requires presence of cytokines and
chemotactic factors which cause activation, expression of adhesion
molecules and recruitment of cells. Sources of these chemokines include
the mast cell and the activated endothelial cell .Endothelial cell activation
is suggested by the presence of intercellular adhesion molecule 1 and
E-selectin in biopsy specimens of urticarial lesions36.
On stimulation, mast cells release both preformed mediators and
newly generated mediators.
Preformed mediators:  heparin, histamine, proteases like tryptase and
chymase37, 12.
Newly generated: leukotrienes C4, D4, E4, platelet activating factor and
prostaglandin D2.
13
Cytokines:   TNF?, IL3, IL4, IL5, IL6, IL8, IL13 and GM-CSF
              Basophils also express  Fc€RI? and release mediators on
activation like histamine, IL4, IL13, LTC412.
Histamine
             Histamine is the most important preformed mediator in the
pathophysiology of urticaria. It is released from mast cells following
degranulation.Increased concentration of histamine has been recovered in
tissue fluid from lesions of urticaria. Histamine release from mast cells is
more in chronic urticaria patients compared to normal subjects. There is no
evidence for decreased skin histamine metabolism in chronic urticaria but
cutaneous vasculature of these patients is more responsive to histamine
than skin of normal controls38.
             Histamine after its release acts on its receptors. Activation of H1
receptor in the skin induces itching, flare, erythema and wealing. H2
receptors activation causes erythema and wealing but not itch or flare. So
far, H3 receptors which are inhibitory autoreceptors present in nervous
system have not been identified in human skin12.
Other mediators
                Tryptase and chymase are preformed mediators released along
with histamine. Tryptase mediate itch by its effect on activation of
14
proteinase activated receptor 2 present on sensory nerve fibre and
endothelial cells39. Chymase can induce mast cell degranulation.  Tryptase
and chymase cleave C3 to C3a and C3b. C3a can activate mast cells and
C3b activates alternate complement pathway12.
TNF? up regulates vascular endothelial adhesion molecules. IL8
stimulates neutrophil activation and accumulation. Some mast cells are
positioned close to nerve endings where histamine stimulates sensory
afferent nerves to release substance P. Neuropeptides appear to be
responsible for the neurogenic axon flare after intradermal histamine
injection12.
Cellular involvement
The dermal cellular infiltrate consists of lymphocytes, neutrophils
and eosinophils. They release a variety of cytokines with pro inflammatory
properties. The observation that the cellular infiltrate in weals of patients
with chronic autoimmune and idiopathic urticaria are similar suggests that
the inflammatory response is determined by the event of mast cells
degranulation rather than its stimulus40.
           Blood basophil levels are reduced in chronic urticaria. They are
actively recruited from peripheral blood into lesional skin by expression of
endothelial adhesion molecules, including VCAM-1, induced by
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degranulation of lesional skin mast cells. Basophil releasability of
mediators is found to be reduced in chronic autoimmune urticaria patients
with antiIgE and anti Fc€RI? antibodies implying that circulating
basophils in these patients may be in a state of desensitization from further
stimulation through the Fc€RI? 41, 43. But this did not apply to skin mast
cells. Basophils also contribute to prolonged duration of weals42.
Autoimmunity
          Autoantibodies play a major role in the pathogenesis of patients with
chronic autoimmune urticaria. These are IgG antibodies directed against
1. Fc€RI?  receptor on mast cell in 30-40%
2. IgE bound to Fc€RI? receptor in 5-10%43, 2, 44.
Anti Fc€RI?
These autoantibodies react with the ?-subunit of the human high-
affinity immunoglobulin E receptor (Fc€RI?). Detection of these
antibodies even in normal healthy individuals indicates that they are part of
natural antibody repertoire unit of immune system45. What makes these
antibodies functional in releasing antibodies by certain set of patients has
been a field of interest. Suggested theories include,
16
Presence of anti idiotype antibodies to the anti Fc€RI?
autoantibodies in healthy individuals and loss of this balance in
autoimmune urticaria patients, rendering them functional to release
mediators. Treatment with IVIG which contains natural antibodies is
believed to restore the unbalanced anti idiotype network and improvement
of symptoms46.
Mechanism of conditional autoimmunity was proposed where
various factors influence the function of these autoantibodies47. The
Fc€RI? receptors are occupied by IgE which blocks the binding of anti-
Fc€RI? autoantibodies to the receptors. When receptor is not occupied by
IgE, the autoantibodies bind and release mediators. Factors influencing this
receptor occupancy include,
1.  Imbalance between the level of anti- Fc€RI? antibodies and IgE.
2.  Amounts of free IgE bound to secreted Fc€RI? chain.
3.  Receptor density may be up regulated or down regulated by levels of
serum IgE.
4.  Actual numbers of cells, and therefore receptors may be increased
for example, during an ongoing allergic inflammation47.
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Anti IgE
These antibodies are detected in 5-10% of autoimmune urticaria
patients. All these antibodies cause mediator release from mast cells and
basophils by cross linking of either the receptor or the IgE attached to the
receptor. Autoantibodies to mast cells may also initiate complement
activation with generation of C5a anaphylotoxin leading to
degranulation43.
The mechanism of histamine release induced by the autoantibody against
Fc€RI? is unusual in that IgE sensitization of basophils is not necessary,
whereas histamine release induced by allergens and anti-IgE antibodies is
dependent on cell-surface IgE48.
Antibody subtypes
The IgG antibodies detected in chronic autoimmune urticaria are
IgG1 and IgG3 subtypes which fix complement49.  In  some  patients
complement inactivation of serum and complement receptor blockade have
shown to inhibit basophil release, suggesting the importance of
complement activation and complement receptor signal transduction
pathway in them50. Mast cells from different sites differ in their expression
of complement receptors; for example, mast cells in the skin express C5a
receptor, but those in the lung do not51. Therefore involvement of
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complement   might explain the localization of mast cell activation mainly
to the skin in CIU.
Positive Immunoblot results for the presence of autoantibodies but
negative functional assay results for basophil histamine release were
observed in autoimmune disorders, such as dermatomyositis, systemic
lupus erythematosus, bullous pemphigoid and pemphigus vulgaris52. The
antibodies detected in these disorders were of IgG2 and IgG4 subclasses.
They are not complement fixing and are not functional and hence unlikely
of pathogenic importance.
In some patients some unidentified non IgG factors are responsible
for mast cell activation. This group of patients react positively to
autologous serum skin test but absence of antibodies in antibody detection
assays.
         Diagrammatic representation of mast cell degranulation by autoantibodies
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Histopathology
The histopathology is usually non specific. There is vascular and
lymphatic dilatation in the dermis with edema. Perivascular inflammatory
infiltrate surrounding small venules of superficial and deep venular plexus
is seen. Infiltrate consists of lymphocytes, neutrophils and eosinophils53.
Presence of eosinophil varies greatly. Even when eosinophils are not
evident, major basic protein can be identified in majority of lesions
indicating prior eosinophil degranulation54.  When  the  histology  of
autoimmune and idiopathic chronic urticaria was compared, the
autoimmune subgroup had more number of granulocytes within the
infiltrate, whereas other infiltrating cells were similar. Increased cytokine
levels in the autoimmune group and greater tryptase positivity in the
autoantibody negative group was also noted40. On electron microscopy,
dermal mast cells show signs of degranulation .The perivascular infiltrate
consisted predominantly of helper T lymphocytes expressing mRNA for
interleukin IL4, IL5 and INF?.
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DIAGRAMATIC REPRESENTATION OF PATHOGENESIS OF AUTOIMMUNE
URTICARIA
Clinical features
Itchy erythematous macules develop into weals consisting of
erythematous edematous raised areas of skin often with a surrounding red
flare. They occur anywhere on the body, including scalp, palms and soles
in variable numbers and sizes ranging from millimeters to lesions covering
large areas and in various shapes including rounded, annular, serpiginous
and bizarre patterns due to confluence of adjacent lesions.
Weals generally last a few hours and resolve within 24 hours
passing through a macular erythematous phase, leaving the skin with
normal appearance. The lesions are very itchy especially at night2, 55.
21
Patients tend to rub rather than scratch, so excoriation marks are unusual.
Occasional bruising may be present.
There may be associated angioedema. These deep swellings which
may be the same colour as normal skin occur most frequently on the face,
eyelids and lips. Any part of the body may be affected such as ears, neck,
hands, feet and genitalia. Mucosal swellings may also occur inside the oral
cavity on the buccal mucosa, tongue and pharynx but laryngeal
involvement is rare. Angioedema may be preceded by an itching or
tingling sensation. Lesions may last for several days12.
         Urticaria may be preceded by vomiting and can be associated with
systemic symptoms of malaise, loss of concentration, low mood, feeling
hot and cold, headache, abdominal pain, diarrhoea, arthralgia, dizziness
and syncope56. In most severe acute form it can present with anaphylaxis.
Chronic autoimmune urticaria in some studies have shown to have
prolonged duration, severe disease manifestation and increased association
with systemic symptoms57.
Associations
Chronic autoimmune urticaria is associated with antithyroid
antibodies in 27% of patients58. Also it is found to be associated with other
auto immune diseases like vitiligo, rheumatoid arthritis, pernicious anemia,
22
and insulin dependent diabetes mellitus. Family history of urticaria or other
autoimmune diseases in the family can be associated59.
Differential Diagnosis
Urticarial weals are distinguished by their evanescent nature and
normal overlying epidermis. Rarely, some diseases can cause difficulty
like papular urticaria, erythema multiforme, prebullous eruptions, drug
eruptions, Still’s disease, mastocytosis, sweet’s syndrome, acute contact
dermatitis, urticarial vasculitis, lymph edema and collagen vascular
diseases like dermatomyositis12,60. But these conditions last longer than 24-
48 hours.
Detailed clinical history is necessary to differentiate chronic
autoimmune urticaria from other causes of urticaria. Information regarding
onset, duration, course of the disease, location, number, size and shape of
weals are important. Weals lasting for more than 24-48 hours associated
with pain suggest possibility of urticarial vasculitis or delayed pressure
urticaria, but can also occur in ordinary urticaria. Biopsy of the lesion can
be helpful in these cases. Possible precipitating or aggravating factors like
heat, cold, localized pressure, friction, sunlight, acute infections, drugs and
food should be ruled out.
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 Investigations
Blood tests   -  Complete blood count
ESR
Skin biopsy (if vasculitis is suspected).
Stool examination for parasites (if infection suspected).
ENT, Dental evaluation to rule out focal sepsis.
Testing for helicobacter pylori (if symptoms of peptic ulcer is present).
Thyroid function test.
Autologous Serum Skin Test (ASST).
Autologous Plasma Skin Test (APST).
Basophil histamine release assay.
Detection of autoantibodies by ELISA / Immunoblot assay.
IgE levels12, 61, 62, 63.
Chronic idiopathic urticaria patients are classified under five subsets
by Ruth et al in one study based on the differences in immunoreactivity
and histamine releasing activity14,
1.  Patients with positive anti Fc€RI? immunoreactivity and positive
histamine releasing activity.
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2.  Patients with positive anti Fc€RI? immunoreactivity but negative
histamine releasing activity.
3.  Patients with anti IgE antibodies.
4.  Serum with ability to release histamine from mast cells but not from
basophils.
5.  No identifiable factors.
          All patients cannot be classified precisely into one of these groups.
Patients with both anti Fc€RI? and anti IgE antibodies have been placed in
group  3  in  this  study14. This classification of chronic idiopathic urticaria
patients helps in identification of basic etiology behind the disease. It
cannot be carried out in all settings as it is expensive and requires expertise
to perform.
          Identification of patients with autoimmune etiology is important in
treatment of this subgroup who are at times resistant to conventional
therapies where some new treatment options to suppress this autoimmunity
can be tried. Autoimmunity can be detected using following tests.
Autologous Serum Skin Tests (ASST)
Autologous serum skin test is a simple in vivo clinical test for
detecting presence of circulating functional autoantibodies to Fc€RI? and
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or  to  IgE5. Although basophil histamine release assay is the “gold
standard” for detecting these functional antibodies, it requires expertise
and fresh basophils from healthy donors. Hence ASST can be used as a
simple screening test for detecting autoimmune urticaria.
Pre requisite
ASST is performed after the patients are off anti histamines for
atleast 3 days (7 days for long acting anti histamines and 2 weeks for
doxepin), cortico steroids and other immuno suppressive agents (for 6
weeks to 3 months). The test is not performed over the areas involved by
weals in the last 24 hours 5, 64.
Procedure
2ml of patient’s venous blood is taken. Blood is allowed to clot
under room temperature. Serum is separated by centrifuging blood at
2000rpm for 10 min. 0.1 ml of this separated serum, 0.1ml of normal
saline, 0.1ml of histamine (10 micro gram/ml) are injected intradermally at
least 5cm apart on the volar aspect of the forearm. Insulin syringe that has
1ml marked as 40 units is used for injection. Every time a separate syringe
is used for each injection.
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After 30 minutes the weal formed at each injection site is measured
at 2 perpendicular diameters (d1&d2) and average is calculated
D = d1+d2/2. Positive ASST is one with serum induced weal which has a
diameter of ? 1.5mm as compared to the saline induced weal at 30
minutes5.
            The reported prevalence of ASST positivity in patients of chronic
urticaria ranges from 25-60% in various studies65,55.  Sera  of  only  half  of
ASST positive patients are able to release histamine from basophils
invitro. Negative ASST patients serum also has shown to contain
antibodies. Studies have been done to explain the variations. The various
scenarios are:
1. ASST positive but negative antibodies on invitro tests
           Some patients react positively to intradermal ASST but show
negative results for anti IgE and or anti Fc€RI? antibody detection66. When
sera of some ASST positive patients were depleted of IgG and then tested
again, wheal and flare reactions have been observed. In these patients
studies have identified the presence of non Ig histamine releasing factors
(HRF) which release histamine from skin mastocytes invivo but fail to
degranulate basophils or mast cells invitro. This has put forward the
hypothesis that non Ig HRFs may exert a direct activity on cutaneous
microvasculature bypassing the cells67.
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2. ASST positive but negative invitro basophil histamine release
          Patients with positive ASST and with presence of antibodies have
shown negative results with basophil histamine release assays68. Sabroe et
al in one study indicates that the cause for unresponsiveness of basophils
might be due to the  autoantibodies recognizing epitopes on recombinant
Fc€RI? used in immunoassays that are inaccessible on cell-surface
receptors14.  Other  possibility  for  the  false  positive  ASSTs  may  be  due  to
the generation of bradykinin during clotting process and cleavage of C5 to
C5a by plasma proteases like tryptases secreted by neutrophils2. Basophil
histamine release by some sera is inhibited when cell-surface  Fc€RI? is
saturated with IgE, as binding site for the anti Fc€RI? autoantibodies are at
or close to the IgE binding site. Dermal mast cells, however, rarely seem to
be fully sensitized with IgE. This can be minimized by using IgE stripped
basophils for the test14, 48.
3. ASST negative but positive antibody detection
               This can be seen in many diseases in which antibodies are of
IgG2 and IgG4 subclass and are non functional detected by their inability
to release histamine from basophils53.
               ASST correlates with severity of urticaria. During remissions
ASST has been found to be negative in previously positive patients9. The
sensitivity of ASST is 70% and specificity is 80%63.
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 Limitations
    Positive ASST has been demonstrated to be associated with
presence of H.pylori antibodies and patients with intolerance to non
steroidal anti inflammatory drugs. It needs expertise for reproducibility and
stopping antihistamines prior to the test in severe cases may be difficult.
Testing over the site of recent weals may alter the results and the results
may sometimes need to be correlated with basophil histamine release test.
Autologous Plasma Skin Test (APST)
APST is done by intradermal injection of autologous plasma
instead  of  serum.  This  is  done  to  prevent  release  of  bradykinin  due  to
clotting of blood in ASST. APST is done by adding anticoagulants other
than heparin as heparin can prevent degranulation of mast cells and
basophils. Studies comparing ASST and APST have shown that 98% of
ASST positive patients showed positive results with APST. 70% of ASST
negative patients have shown positive result with APST denoting an
increased specificity of APST. The APST positivity and measurement of
prothrombin fragments indicate the role of thrombin in chronic
urticaria69.Thrombin increases vascular permeability, causing edema and is
able to trigger mast cell degranulation. In some mast cell population,
thrombin response was equipotent with Fc€RI? mediated activation.
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 Diagnosis of Autoimmune Urticaria: In-Vitro Tests
Histamine release assay
                This is the gold standard test for the detection of autoimmune
urticaria. It detects the functional activity of the serum. This is done by
incubating patient serum with basophils or dermal mast cells and detection
and measurement of histamine or other mediators released34.
               Basophils are obtained from healthy donors and dermal mast cells
are obtained from skin removed during circumcision70. Alternatively, rat
basophil leukemia cell line transfected with genes to code for Fc€RI? can
be used71. Basophils used should have both IgE sensitized cells and IgE
striped cells (done by lactic acid) for detection of anti IgE and anti- Fc€RI?
autoantibodies respectively34, 72.
Antibody detection
Anti  IgE  and  anti-  Fc€RI? auto  antibodies  can  be  detected  using
following tests71
1. ELISA
2. Western blot
3. Immunoblotting
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Subclass identification of IgG autoantibodies helps in detecting
functional and non functional activity.
IgE levels
          Elevated IgE levels are detected in chronic urticaria patients.
Association has been noted between increased total IgE levels with severe
chronic urticaria, positive ASST and antithyroid antibodies72.
Management
Initial treatment of chronic urticaria is same regardless of patient
having autoimmune etiology or not. However Patients with chronic
autoimmune urticaria are poor responders to conventional antihistamine
therapy. In these patients other therapeutic options can be tried. But
antihistamines are the first line drugs to be used.
Antihistamines
Antihistamines are the main stay of treatment in all forms of
urticaria, as histamine is the main mediator of urticaria4. First generation
Classical H1 antihistamines like chlorpheniramine, hydroxyzine,
diphenhydramine, etc have side effects including sedation, anti cholinergic
effects and paradoxical excitation in children73. Newer H1 antihistamines
include fexofenadine, loratadine, desloratadine, cetirizine, levocetrizine,
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ebastine, mizolastine, olapatadine, rupatadine, etc. Second-generation
antihistamines should be considered as the first-line symptomatic treatment
for urticaria because of their good safety and tolerability profile. Main
advantage is low sedation and minimal anti cholinergic side effects74.
Higher doses of second generation antihistamines are effective in severe
chronic urticaria. Studies using even up to fourfold higher than
recommended doses of desloratadine, fexofenadine, levocetrizine and
rupatadine can be used75, 76. Two long-term studies in healthy volunteers
have demonstrated that fexofenadine, at doses up to 240 mg once daily for
up to 12 months, is safe and well tolerated77. No dose-related increases in
corrected QT interval (QTc) were found with fexofenadine doses up to 800
mg once daily or 690 mg twice daily for 28 days74. Fexofenadine does not
lead to sedation even at supratherapeutic doses. Cetirizine causes sedation
at therapeutic and supratherapeutic dose, whereas levocetrizine and
desloratadine cause sedation at supratherapeutic dose78
In some cases combination of H1 antihistamine with H2
antihistamine may be more effective than H1 antihistamines alone79. Use
of ranitidine 150mg twice a day is preferable to cimetidine which has more
antiandrogenic side effects and potential drug interactions.
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Antihistamines cross the placenta. There is no reliable evidence that
they are teratogenic but they should be avoided in pregnancy particularly
in the first trimester. If not possible, chlorpheniramine appears to be least
risky to use12, 80. Certain antihistamines have been proposed as preferred
for particular subtypes of chronic urticaria, such as hydroxyzine for
cholinergic urticaria or cyproheptadine for cold induced urticaria81.
Although antihistamines are very effective in controlling the
symptoms, it is being increasingly realized that these drugs act only at the
peripheral  level  and  mask  the  symptoms.  They  do  not  alter  the  course  of
the disease that is why in chronic urticaria the symptoms tend to reappear
whenever the drug is withdrawn.
Leucotriene receptor antagonists
Zafirlukast (20 mg twice daily) and montelukast (10 mg once daily)
are effective in treatment of chronic urticaria especially in cases which
were aggravated by the NSAIDs and food additives. Zileuton, a 5-
lipooxygenase inhibitor, which inhibits Leucotriene generation is also
effective82.
Tricyclic antidepressants
Doxepin is a tricyclic antidepressant with very potent H-1 and H-2
antihistaminic properties. Doxepin is more effective than diphenhydramine
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at a dosage of 10 mg thrice daily. Doxepin should not be advised after a
recent myocardial infarction or for patients with severe liver disease. It is
best to start at a low dose of 10 mg daily at night, which can be increased
to 20 or 30 mg a day83, 84.
Corticosteroids
             Oral corticosteroids are effective in severe urticaria not controlled
with antihistamines. Dose of 0.5–1mg of prednisolone/kg/day can be
given7. Steroids do not inhibit mast cell degranulation but affect the
function and cytokine production by inflammatory cells85.  Long  term
dosage should be avoided because of risk of side effects86. Short term
alternate day regimen can be used for severe, persistent episodes87.
Autologous serum therapy (AST)
AST  is  an  effective  treatment  option  for  patients  with  chronic
autoimmune urticaria identified by ASST. It is given by injecting patients
own serum as a weekly once intramuscular injection for a period of 9
consecutive weeks. 5 ml of patient blood is drawn and centrifuged at
2000rpm for 10 minutes. 2ml of the separated serum is injected as deep
intramuscular injection5. Previously whole blood was drawn and injected
(autohemo therapy) 88,  89. But this was very painful and the injections
should be given immediately .This was replaced by serum therapy as the
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antibodies are concentrated in the serum than the cellular components of
blood.
Studies conducted on AST in chronic autoimmune urticaria patients
have shown variable results. The exact mechanism by which AST acts is
not known, one study indicated 60% patients had significant improvement
in their signs and symptoms5. Relapse of symptoms have been noted
during follow-up which responded with booster dose of AST. Interesting
finding  in  the  study  by  Bajaj  et  al. is that, the ASST-negative group
responded almost equally well to AST as the ASST-positive group.
Existence of a subset of patients with autoimmune urticaria who are ASST-
negative may  be considered as a possibility for the response87.
AST is a cheap, effective and potentially curative modality in some
patients with recalcitrant chronic urticaria.
Calcium channel blockers
Limited evidence shows that calcium channel blocker, nifedipine at
dosage of 10 mg twice daily to 20 mg three times daily used in
combination with antihistamines, has added effect in patients who have not
responded to antihistamines alone90.
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Immuno modulators
Cyclosporine
             Various studies have been conducted for the effect of cyclosporine
in chronic urticaria. Dose use ranged from 3-6 mg/kg/day91, 92.  In  a
randomized doudle blinded study, 4mg/kg of cyclosporine administered
over 4 weeks resulted in a significant response93. In other randomized
study dose of 5mg/kg slowly tapered to 3mg/kg was given over a period of
16 weeks94. It is useful in patients with severe chronic urticaria. It spares
the need for corticosteroids. In autoimmune urticaria patients, significant
reduction of  invitro histamine-releasing activity and reduction in reaction
size  of  the  autologous  serum  skin  test  was  seen  after  cyclosporine
treatment95. Mechanism of action is by inhibition of basophil and mast cell
degranulation by interfering with intracellular signaling in cells following
recptor cross linking87.
Methotrexate
There are only few case reports of methotrexate use in chronic
urticaria. No randomized control studies are available for its use in chronic
autoimmune urticaria. Gach et al reported its use in two patients with
severe chronic idiopathic urticaria96. Dose of 2.5 mg orally twice daily for
two days in a week was tried in a study on chronic autoimmune urticaria
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patients who were refractory to treatment with antihistamines. Treatment
was given for two months along with antihistamines. After a course of
treatment patients were controllable with antihistamines alone97.
Warfarin
Dose of 2-5 mg/day  of warfarin for 2-5 months has been shown to
benefit patients not controlled with antihistamines and requiring daily dose
of steroids. A double blind placebo controlled study conducted by Parslew
et al on chronic idiopathic urticaria patients has shown significant benefit
in reduction of pruritus and angioedema with warfarin98. The mechanism
of  warfarin  action  is  by  suppression  of  thrombin,  a  potent  mast  cell
degranulator and proteins in the coagulation cascade99. Involvement of the
extrinsic coagulation pathway in chronic idiopathic urticaria has been
demonstrated, providing the rationale for anticoagulant use100. Repeated
prothrombin time monitoring is important to avoid major adverse effects
like bleeding. PT INR should be maintained between 2 and 2.5. In chronic
urticaria patients with and co existing diseases requiring long term
warfarin like deep vein thrombosis, atrial fibrillation and recurrent
pulmonary embolism this therapy may be considered101.
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Omalizumab
 Omalizumab is a recombinant humanized monoclonal antibody that
selectively binds to IgE. In chronic autoimmune urticaria patients it acts by
inhibiting the binding of IgE to the high affinity IgE receptor (Fc€RI?) on
the surface of mast cells and basophils and by sufficient reduction in
Fc€RI? expression on the surface of these cells. It prevents IgG antibody-
mediated cross-linking of adjacent ? subunits causing mediator
release102,103,104.
           Dosing is based on weight and is administered via subcutaneous
injection every 2-4 weeks103. Dose tried is 300mg once a month. The safety
profile of omalizumab is favorable with injection site reaction being the
most commonly reported adverse event102.
Intravenous immunoglobulin
Intravenous immunoglobulin dose of 0.4gm /kg/day for 5 days was
effective in relieving symptoms and achieving ASST negativity in chronic
autoimmune urticaria patients. Long term remissions were reported46.
Permanent remission was noted in patients attaining ASST negativity
within 6 months of therapy. High dose of 2g/kg over 24 hours was also
used successfully105. Possible mechanism of action is by the presence of
anti idiotype antibodies suppressing the IgE autoantibodies106.
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Cyclophosphamide
Use of cyclophosphamide was reported by Bernstein et al in woman
with severe chronic autoimmune urticaria. Initial dose given was 500 mg
every 2 weeks, increased by 100 mg every 2 weeks till a maximum of 1500
mg was reached, which was continued every 4 weeks. Complete clinical
remission was noted in 7 months. Repeat ASST was negative. Possible
mechanism of action is that, cyclophosphamide may have eradicated B-cell
clones that were producing autoantibodies to the high-affinity IgE receptor.
This study is the only known report of the use of this agent in chronic
urticaria107.
Plasmapheresis
Plasmapheresis  was found to be beneficial  in a study conducted on
eight patients with chronic autoimmune urticaria. It may act by eliminating
the functional autoantibodies from body. A decrease in the size of the skin
test reaction to autologous serum after plasmapheresis was noted15.
Dapsone
Dose of 50 mg/day of dapsone was used in a study on a patient with
chronic urticaria not controlled with antihistamines and required large
doses of steroid. The mechanism responsible for clearing may be by down
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regulation of leukotriene B4 (LTB4) and/or interference with CD11b, which
has shown to play a role in chronic urticaria108.
Others
Other modalities tried include,
Sodium cromoglycate in a dose of 200 mg four times daily was used
in a study. It inhibits release of mediators from mast cell, by interfering
with calcium transport across the mast cell membrane109. Patients with
chronic urticaria and thyroid autoimmunity   may improve with thyroxine
treatment110.
Other drugs found to be helpful in small studies or case reports,
include, colchicine, hydroxychloroquine111, oral tacrolimus112,
mycophenolate mofetil113, PUVA114 and sulphasalazine115.
Future possibilities
More selective immunotherapies are possibilities. The extracellular
part of the ? subunit of Fc€RI? or shorter peptide sequences containing the
autoantibody epitopes could be used to bind to circulating Fc€RI?
autoantibodies, thereby inhibiting their attachment to receptors on mast
cells or basophils4.
Aim of the study
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AIM OF THE STUDY
1.  To study the prevalence of chronic autoimmune urticaria among
patients with chronic idiopathic urticaria using autologous serum
skin test.
2.  To study the epidemiological pattern of chronic autoimmune
urticaria.
3.  To evaluate the efficacy of autologous serum therapy in patients
with chronic autoimmune urticaria.
Materials and
methods
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MATERIALS AND METHODS
Study design: Prospective, Interventional study.
Study period : Oct 2009 to Sep 2011.
Study population : 200 consecutive patients with chronic idiopathic
urticaria attending our dermatology OP were selected for the study
The study was approved by the Institutional Ethical Committee,
Rajiv Gandhi Government General Hospital & Madras Medical College,
Chennai. All patients signed a written informed consent document.
Diagnosis of chronic urticaria was done based on the history and
clinical examination. History of drug intake, aggravating food, urticaria
following infections, allergy to house dust, pollen, animal danders, history
of episodes following exposure to cold/heat/pressure/sunlight/exercise,
history of dental/ortho implants was taken to rule out other causes of
urticaria.
Details from the history included in the study
1.  Age
2.  Sex
3.  Total duration of the disease
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4.  Frequency of episodes
5.  Number of weals
6.  Severity of pruritus
7.  Duration of each episode
8.  Frequency of AHT use
9.  Size of weals
10.  Associated atopy / angiodema
Scoring
Following scoring was done based on the history to grade the severity of
the disease.
1.  Number of Weals score
0 – none
1 -  ? 10
2 – 11 to 50
3 - >50
2.  Pruritus score
0 – Absent
1 – Present but not disturbing
2 – Disturbing but not hampering sleep / day time activity
3 – Hampering day time activity / sleep
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3.  Frequency of weal score
0 – none
1 - < once / once a week
2 – 2 to 3 times a week
3 – Almost daily / daily
4.  Duration of weal score
0 – none
1 - < 1 hour
2 – 1 to 12 hours
3 - >12 hours
5.  Score for antihistamines use
0 – None
1 - < once / once a week
2 – 2 to 3 times a week
3 – Almost daily / daily
6. Size of weal score
0 – None
1 - < 1cm
2 – 1 to 3 cm
3 - > 3 cm
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Total severity score (TSS)
TSS   is  calculated  by  adding  the  scores  for  number  of  weals,
pruritus, frequency of weal, duration of weal, antihistamine use and size of
weal.
Maximum TSS is 18. Based on the TSS value patient’s disease
severity was graded as follows:
TSS  SCORE GRADE
0 clear
1 – 6 mild
7 – 12 moderate
13 - 18 severe
Inclusion criteria for ASST
Patients with chronic idiopathic Urticaria.
Duration of weals for more than six weeks.
Patients more than 12 years of age.
Willingness for the test.
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Exclusion criteria for ASST
Urticaria due to medications, insect bites, food allergy, following
acute or chronic infections or other known etiology(from history).
Physical Urticaria and hereditary angioedema.
Less than 12 years of age.
Pregnant and lactating women.
Inclusion criteria for AST
Patients with positive ASST.
Willingness for weekly injections.
Willingness for follow up.
Exclusion criteria for AST
Patients with negative ASST.
Pregnant and lactating women.
Age less than 12 years
Investigations performed to rule out other causes are
Complete blood count
Urine routine
Liver function test
Renal function test
Stool examination
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ENT and dental examination to rule out focal sepsis
Materials required
Sterile 2 ml and 5 ml syringes
Sterile test tubes
Centrifuge
Insulin syringes
Normal saline
Prerequisites for ASST
Patient should be free from drugs that can cause false negative
reactions. If patients had taken the following drugs, ASST was done after
the wash out period for the drugs.
Drug Wash-out period
Corticosteroids –
Parenteral   (IM, intra-articular)
Oral Corticosteroids
Topical Corticosteroids
Inhaled Corticosteroids
? 90 days
? 30 days
? 14 days
? 30 days
Antihistamines - Astemizole
                            Loratidine
? 60 days
? 7 days
MATERIALS  REQUIRED  FOR  AUTOLOGOUS  SREUM  SKIN  TEST
CENTRIFUGE MACHINE
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Drug Wash-out period
Certizine,Terfenadine, Fexofenadine
Hydroxyzine, Ebastine, Azatadine
? 72 hours
? 72 hours
H2 Antagonists ? 72 hours
Other H1 antagonists ? 24 hours
Cough / Cold preparations ? 24 hours
Sedatives & hypnotics ? 24 hours
Tricyclic antidepressants ? 21 days
Phenothiazines, Benzodiazepines ? 21 days
NSAIDS & Narcotic analgesics ? 72 hours
Procedure
Method of serum separation
1.  Two ml patient’s venous blood is taken from antecubital vein.
2.  Blood is allowed to undergo clotting at room temperature.
3. Serum is separated by centrifugation done at 2000 rpm for 10
minutes.
Test
0.1 ml of the seperated serum is injected intradermally using an
insulin syringe into the volar aspect of forearm, avoiding the areas of
wealing within the past 24 hours.
 2 ML  BLOOD  COLLECTED  FOR ASST               SERUM SEPERATED FROM 2 ML  FOR ASST
     5 ML BLOOD COLLECTED FOR AST                   2 ML OF SERUM SEPERATED FOR AST
TECHNIQUE OF AUTOLOGOUS SERUM SKIN TEST
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Control
 Equal amounts of normal saline is  injected intradermally using
separate insulin syringe 3 to 5 cm apart in the volar aspect of the same
forearm for negative control.
Reading
Wheal and flare response is measured after 30 min.
Vertical diameter (d1), horizontal diameter (d2) are measured and
average diameter D is calculated as D = d1+d2/2
Positive test
Positive result is defined as  the serum induced weal with a diameter
of  ? 1.5 mm as compared to the saline induced weal.
Autologous serum therapy
Method of serum separation
1.  Five ml of patient’s venous blood is taken from antecubital
vein.
2.  Blood is allowed to undergo clotting at room temperature.
3.  Serum is separated by centrifugation at 2000rpm for 10
minutes.
POSITIVE RESULT OF AUTOLOGOUS SERUM SKIN TEST
NEGATIVE RESULT OF AUTOLOGOUS SERUM SKIN TEST
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Therapy
2 ml of the separated serum is given as deep intramuscular injection
in alternate buttock once a week for a period of 9 consecutive weeks.
Rescue antihistamines were permitted during therapy period when
symptoms occur and their frequency of use noted for scoring. All patients
were given Tab.cetrizine uniformly, to be used as rescue therapy when
need arises.
Follow up
Patients were asked to come for follow up after 3 months of last
injection. Repeat scoring is done and TSS is calculated.
Statistical analysis
Statistical analysis was performed using chi-square test,
independent t test and paired t test. P values <0.05 was considered
significant. Comparison between ASST positive and ASST negative
patients was done  in relation to
Age
Sex distribution
Duration of disease
Atopy
Angioedema
TSS
CLINICAL  PHOTOGRAPH  OF  URTICATIAL  WEALS
URTICARIAL WEALS ON THIGH
ANGIOEDEMA OF HAND
Observations and
results
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OBSERVATION AND RESULTS
200 consecutive patients of chronic idiopathic urticaria satisfying the
study criteria were selected for the study.  Of the total 200 patients 85
(42.5%) were males and 115 (57.5%) were females.
Table 1 : sex distribution of chronic urticaria
GENDER FREQUENCY PERCENT
Male 85 42.5
Female 115 57.5
Total 200 100.0
1. PREVALENCE OF AUTOIMMUNE URTICARIA
ASST  was  performed  on  200  patients  using  autologous  serum.  Of
which 153(76.5%) were negative for ASST and 47(23.5%) were positive.
Table 2: Prevalence of  chronic autoimmune urticaria
ASST RESULT FREQUENCY PERCENT
Negative 153 76.5
Positive 47 23.5
Total 200 100.0
Based on ASST results, patients are grouped into two groups, ASST
positive and ASST negative. Age, sex, duration of disease, Total Severity
Score (TSS), association with atopy/angioedema was compared between
MALES
42%
FEMALES
58%
SEX  RATIO OF CHRONIC IDIOPATHIC
URTICARIA
MALES
FEMALES
ASST
NEGATIVE
153 MALES
22
FEMALES
25ASST
POSITIVE
47
PREVALENCE AND SEX DISTRIBUTION OF
AUTOIMMUNE URTICARIA
51
the two groups. TSS was calculated based on parameters like frequency of
appearance of weals, number of weals during each episode, pruritus score,
duration of each episode, AHT use and size of weals.
2. SEX DISTRIBUTION
Table 3 : Comparison of sex distribution
ASST RESULT
GENDER
P ValueMale Female
NUMBER % NUMBER %
       Negative 63 74 90         78
0.5048       Positive 22 26 25 22
       Total 85 100.0 115 100.0
Of the total 47 ASST positive patients, 22(47%) were males and
25(53%) were females. Of the total 153 ASST negative patients,
63(41.17%) were males and 90(58.82%) were females. There was no
statistical significance in the sex distribution between ASST positive and
negative patients(P=0.5048).
3.  AGE DISTRIBUTION
Table 4 : Comparison of mean age
ASST
RESULT
NO  OF
PATIENTS
AGE IN YEARS
P VALUEMEAN STDDEVIATION
Positive 47 36.77 14.55
0.535
Negative 153 35.42 12.48
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Table 5 : Comparison of age distribution
AGE   GROUP ASST    POSITIVE ASST NEGATIVE
12-20 7 16
21-30 12 51
31-40 12 44
41-50 6 22
51-60 8 13
>60 2 7
TOTAL 47 153
Mean age in ASST positive patients was 36.77±15 yrs and in
ASST negative patients were 35.42±13 yrs. There was no statistical
difference in the age distribution between ASST positive and negative
groups (P value is 0.535).
4. DURATION OF DISEASE
Table 6 : Comparison of total duration of disease
TOTAL DURATION ASST POSITIVE ASST  NEGATIVE
<1 year 24 102
>1 to <3 yrs 9 36
>3 to <5 yrs 7 5
>5 years 7 10
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Table 7 : Comparison of mean for total duration of disease
ASST
RESULT
NO  OF
PATIENTS
DURATION  IN  YEARS
P VALUEMEAN STDDEVIATION
Positive 47 4.36 2.78
0.142
Negative 153 3.58 3.29
Mean duration of disease in ASST positive group was 4.36±3 years
and in ASST negative group was 3.58±3  years. There was no statistical
significance in the age distribution between two groups (P value = 0.142).
5. ATOPY
Table 8 : Comparison  of association with atopy
ASST
RESULT
                 ATOPY
P VALUE
    PRESENT      ABSENT
Negative 42 111
     0.852Positive 14 33
Total 56 144
In the ASST positive group out of 47 patients, atopy was present in
14 patients (29.78 %). In the ASST negative group out of 153 patients,
atopy was present in 42 patients (27.45 %). There was no statistical
significance of association with ASST result and atopy (P=0.852).
6. ANGIODEMA
In the ASST positive group out of 47 patients, angiodema was
present in 28 patients (59.57%). In the ASST negative group out of 153
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patients, angiodema was present in 52 patients (33.98%). There was
statistically significant  association with  angiodema in the ASST positive
group compared to ASST negative group(P = 0.002).
Table 9 : Comparison of association with angioedema
ASST
RESULT
ANGIODEMA
P  VALUE
RESENT ABSENT
Positive 28 19
0.002Negative 52 101
Total 80 120
7. FREQUENCY SCORE
In ASST positive group, 1(2.13%) had score 1, 14(29.78%) had
score 2 and 32 patients (68.08 %) had score 3. In ASST negative group,
65(42.48%) had score 1, 55(35.94%) had score 2 and 33 patients (21.56 %)
had score 3. ASST positive patients had more frequent episodes of
urticaria than negative group. There was statistical significance in
frequency score between two groups(P<0.001).
Table 10 : Comparison of frequency score
ASST
RESULT
FREQUENCY SCORE      P
VALUE
1 2 3
Positive 1 14 32
<0.001Negative 65 55 33
Total 66 69 65
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8. NUMBER OF WEALS SCORE
Table 11 : Comparison of score for number of weals
ASST
RESULT
NUMBER OF WEALS SCORE
P  VALUE
1 2 3
Positive 3 22 22
0.926Negative 12 73 68
Total 15 95 90
Out of 47 ASST positive patients, 3(6.34%) patients had score
1, 22(46.8 %) had score 2 and 22(46.8 %) had score 3. Out of 153 ASST
negative patients 12(7.84%) had score 1, 73(47.71 %) had score 2 and
68(44.44%) had score 3. There was no statistical significance between two
groups (P=0.926).
9. PRURITUS   SCORE
In the ASST positive group, 42.55%(20 patients) had score 3,
46.80%(22 patients) had score of 2 and only 10.63%(5 patients) had
score 1. In ASST negative group 29.41 %(45 patients) had score 1,
42.48%(65 patients) had score 2 and 28.10% (43 patients)had score 3. The
difference in the severity between two groups was statistically
significant(P=0.022).
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Table 12 : Comparison of pruritus score
ASST
RESULT
PRURITUS  SCORE
P VALUE
1 2 3
Positive 5 22 20
0.0223Negative 45 65 43
Total 50 87 63
10. AHT USE
In the ASST positive group none of them had score 0, 3(6.38%)
patients had score 1, 13(27.66%) had score 2 and 31(65.96%) had score 3.
In ASST negative patients 13(8.49 %) patients had score 0, 79(51.63%)
had score 1, 44(28.76%) had score 2 and 17(11.11%) had score 3. Score 0
indicated that patients had mild symptoms which was tolerated without any
treatment. The difference in the score between two groups was statistically
significant (p<0.001).
Table 13 : Comparison of score for antihistamine requirement
ASST
RESULT
AHT  USE SCORE
P VALUE
0 1 2 3
Positive 0 3 13 31
<0.001Negative 13 79 44 17
Total 13 82 57 48
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11. DURATION OF WEALS
Table 14 : Comparison of weal duration score
ASST
RESULT
WEAL   DURATION   SCORE
P VALUE
1 2 3
Positive 19 15 13
0.0015Negative 82 59 12
Total 101 74 25
In ASST positive group 19(40.42%) patients had score 1,
15(31.91%) had score 2 and 13(27.65%) had score 3. In ASST negative
group 82(53.59%) patients had score 1, 59(38.56%) had score 2 and
12(7.84%) had score 3. Percentage of patients having severe score was
higher in ASST positive group while majority of ASST negative group had
score 1.The difference was statistically significant (P=0.0015).
12. WEAL SIZE
In ASST positive patients around 19.14 %( 9 patients) had score 1,
63.83 %( 30 patients) had score 2 and 17.02 %( 8 patients) had score 3.
In ASST negative patients 37.91 %( 58 patients) had score 1, 49.67%
(76 patients) had score 2 and 12.42% (19 patients) had score 3. Percentage
of patients having severe score was higher in ASST positive group. There
was no statistical significance between two groups in the weal size score
(P=0.057).
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Table 15 : Comparison of score for weal size
ASST
RESULT
WEAL   SIZE  SCORE
P VALUE
1 2 3
Positive 9 30 8
0.057Negative 58 76 19
Total 67 106 27
13.  TOTAL SEVERITY SCORE (TSS)
TSS is calculated for a patient by adding all the six scores. In ASST
positive patients 59.57 %( 28 patients) had severe TSS score, 38.29 %( 18
patients) had moderate TSS and 2.13 %( 1 patient) had mild TSS. In ASST
negative patients 68.62 %( 105patients) had moderate TSS, 20.92 %( 32
patients) had severe TSS and 10.46 %( 16 patients) had mild TSS. There
was significant difference in the TSS between groups, majority of ASST
positive patients having severe TSS and majority of negative patients
having moderate TSS score. The mean TSS between two groups was also
significant.
Table 16 : Comparison of TSS grade between  two groups
ASST
RESULT
TSS   GRADING
( IN   NUMBER   OF   PATIENTS) P VALUE
MILD MODERATE SEVERE
Positive 1 18 28
< 0.001Negative 16 105 32
Total 17 123 60
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Table 17 : Comparison of mean TSS
ASST
RESULT
NO  OF
PATIENTS
MEAN
TSS
STD
DEVIATION
P VALUE
Positive 47 13.829 2.884
<0.0001Negative 153 10.79 2.925
14. AUTOLOGOUS SERUM THERAPY (AST)
AST was offered to all ASST positive patients. One patient denied
treatment. 46 patients were given AST. Only 44 completed 9 weeks of
therapy, two patients dropped out. Of the 44 patients who completed
treatment only 41 came for follow up, follow up lost for 3 patients.
Table 18 : Number of patients  completed treatment and follow up visit
PARAMETERS NO OF PATIENTS
Total asst positive 47
AST given 46
Completed 9 weeks
of treatment
44
Follow up 41
At baseline majority of patients (25/57%) had severe symptoms and
none of them was free from symptoms. Whereas At end of treatment none
had severe TSS, 9(20%) were free from symptoms and majority had only
mild TSS.
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Table 19 : Comparison of mean and grade of TSS at different stages
TIME
NUMBER
OF
PATIENTS
TSS
(MEAN)
TSS  GRADE  IN  NO  OF  PATIENTS
CLEAR MILD MODERATE SEVERE
Base  line 44 13.68 0 1 18 25
End of
treatment
44 3.68 9 31 4 0
Follow  up 41 3.98 7 25 8 1
9 patients had complete clearance at the end of treatment. During
follow  up  7  out  of  9  patients  remained  clear  with  no  symptoms.  Of  the
remaining 2 patients, follow up was lost for one patient and other patient
had  relapse  of  symptoms with  TSS of  3.  1  patient  relapsed  back  to  have
severe TSS. Though there was a slight increase in the mean TSS at follow
up compared with the mean TSS at end of treatment, the difference was
not statistically significant. None of the patients reached their baseline TSS
value in the follow up period.
Table 20 : Comparison of mean TSS at base line and at end of treatment.
Time points No ofpatients Mean
Std.
Deviation P-Value
Base line 44 13.68 2.90
<0.0001
End of trt 44 3.68 2.55
Table 21 : Comparison of mean TSS at end of treatment and at follow up.
Time points No ofpatients Mean
Std.
Deviation P-Value
End of trt 41 3.73 2.55
0.681
Follow up 41 3.98 2.93
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Table 22 : Comparison of mean TSS at base line and at follow up.
Time points No ofpatients Mean
Std.
Deviation P-Value
Base line 41 13.78 2.97
<0.0001
Follow up 41 3.98 2.93
The mean base line TSS value of 44 treatment completed patient
was 13.83 and at end of treatment it was 3.68. Follow up mean TSS of 41
patients was 3.98. There was significant reduction in mean TSS on
comparing base line with end of treatment (p value <0.0001) and base line
with follow up (p value <0.0001). No significant difference was noted
between mean TSS at end of treatment and follow up.
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DISCUSSION
Chronic urticaria is a common disease, for which at times cause is
not found. These patients with chronic idiopathic urticaria are sometimes
difficult to treat. This study was done to find out patients with autoimmune
etiology  by  doing  ASST  and  to  evaluate  the  efficacy  of  therapy  with
autologous serum in them.
Prevalence of autoimmune Urticaria
In our study with 200 chronic idiopathic urticaria patients, the
prevalence of patients with autoimmune urticaria was 23.5 %.
Historically Grattan et  al  were the first  to use ASST on 12 patients
to differentiate chronic autoimmune urticaria from chronic idiopathic
urticaria.  Out  of  12  patients  7  were  positive  in  that  study9. The reported
prevalence of ASST positivity in patients of chronic urticaria ranges from
25-60% in various studies.
 Study done by Bajaj et al in 394 patients showed ASST positivity in
49.5 %5.  Godse et al conducted study on 45 patients and found 26.67%
were ASST positive116.  Out of 96 patients 53% were positive in a study by
Asero  et  al69.The prevalence of ASST positive patients in our study was
little lower compared to other studies.
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Sex distribution
In our study out of 47 ASST positive patients, 22 (47%) were males
and 25(53%) were females. In ASST negative patients 58.82 % were
females  and  41.17%  were  males.  Male  to  female  ratio  in  ASST  positive
group was 0.8:1 and in ASST negative it was 1:1.42. There was no
statistical significance in sex distribution between positive and negative
group.
Increased female ratio in both groups noted in our study was
comparable with the study conducted by Vohra et al in which  female ratio
was higher in both ASST positive [M: F; 1:2.07] and ASST negative [M:
F; 1:1.25], but there was no statistical significance117.  In  other  study  by
Zeinab abdel azim et al on 35 patients, all 15 ASST positive patients were
females118. But no statistical significance was noted between positive and
negative group.
Age distribution
Age of patients ranged from 12 to 71 years in our study. Mean age
in ASST positive patients was 36.77±15 years and in ASST negative it was
35.42±13 years. There was no significant difference noted in our study
which corroborates with the study conducted by zeinab et al in which age
of patients ranged from 7 to 57 years118. Mean age noted in their study was
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34±10 yrs for ASST positive patients and 30±11 years in ASST negative
patients with no statistical significance. Our study was  in concordance
with studies by Bajaj et al and Zeinab et al5,118.
Duration of disease
In our study duration of disease ranged from 2 – 180 months. Mean
duration of  disease in ASST positive group was 4.36±3 years and in ASST
negative group was 3.58±3 years.
Mamatha et al and sabroe et al in their separate studies have noted
decreased median duration of disease in ASST positive patients compared
to negative ASST group65. However in a 5 year follow up study conducted
by Toubi et al, ASST positive patients had longer duration of the
disease119. Staubach et al also noted longer duration in ASST positive
patients89.
Though  there  was  no  statistical  significance  in  the  age  distribution
between two groups  (P value = 0.1428) in our study, the mean duration of
disease was longer in ASST positive patients which was comparable with
studies by Toubi et al and Staubach et al119,89.
Association with atopy
In  our  study  30  %  of  ASST  positive  patients  and  28  %  of  ASST
negative patients had atopy. There was no statistical significance.
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In  a  study  by  Bajaj  et  al  atopy  was  present  in  46.7%  of  ASST
positive patients and 38.5 % of ASST negative patients. No significant
difference was noted5.  In  the  Study  by  De  Swerdt  et  al  32%  of  ASST
positive patients and 31% of ASST negative patients had atopy. No
significant difference was noted120. Our study results was in concordance
with the results of the above studies.
Association with angiodema
In our study out of total 200 patients, 80 (40%) patients had
angiodema. 28(59.57%) of  ASST positive patients and 52(33.98%) of
ASST negative had angioedema. The difference was statistically
significant.  In  study  by  Vohra  et  al  59%  of  ASST  positive  patients  and
52% of ASST negative patients had angioedema117. In a study by Zeinab et
al 46.7 % of ASST positive and 40% of ASST negative patients had
angioedema118. In both these studies the difference was insignificant.
Whereas  In  a  5  years  follow  up  study  conducted  by  Toubi  et  al,  88%  of
angioedema positive patients and 80% of angiodema negative patients had
urticaria at 12 month and at 5 years, 45% of patients with existing
angiodema had urticaria compared to only 12% of angiodema negative
patients. They noted a strong association between chronic urticaria
duration and presence of angiodema119.
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Severity scores
Frequency score
In our study 68% of ASST positive patients had score 3 whereas
only 21.56% of ASST negative patients had score 3. ASST positive
patients had more frequent episodes of urticaria than negative group.
Statistical significance was noted on comparing the frequency score
between two groups (P < 0.001).
Our  study  results  corroborates  with  the  results  of  the  study
conducted by Mamatha et al, in which statistically significant difference in
the frequency of attacks was noted on comparing ASST positive and ASST
negative group with ASST positive patients having increased
frequency(p=0.038)65. Similar correlation with increased frequency and
ASST positivity was noted in study by Sabroe et al40.
Number of weals score
Out of 47 ASST positive patients, 3(6.34%) patients had score 1,
22(46.8 %) had score 2 and 22(46.8 %) had score 3. Out of 153 ASST
negative patients 12(7.84%) had score 1, 73(41.71 %) had score 2 and
68(44.44%) had score 3. There was no statistical significance between two
groups (P=0.926).
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Our  results  correlated  with  the  study  by  Bajaj  et  al  in  which  there
was no difference in the number of weals between ASST positive
(mean=2.4±0.1) and ASST negative patients (mean=2.4±0.2)5. Whereas in
a study by Sabroe et al significant difference in the number of weals score
was noted with higher mean value in patients with histamine releasing
activity (mean=2.3) compared to patients with no histamine releasing
activity(mean=1.5)40. No significant difference in the mean was noted in
our study between ASST positive (2.40 ± 0.6) and ASST negative (2.37 ±
0.6) groups.
Pruritus and AHT use
In the ASST positive group majority of patients had severe score for
both pruritus and AHT use.   In ASST negative group considerable number
of patients had score 1(29 %) for pruritus and 13 patients (8.40%) had
score 0 for AHT use. The difference was statistically significant with
ASST positive  patients having  severe score for pruritus and higher
requirement for antihistamines. There was also significant difference in the
mean values for pruritus score (2.3 ± 0.6 for ASST positive and 1.98 ± 0.7
for ASST negative) and AHT use score (2.59 ± 0.6 for ASST positive and
1.42 ± 0.8 for ASST negative) in our study.
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Our study results  was in concordance with study by Staubach et  al
on chronic urticaria patients in which longer duration of disease and more
antihistamine requirement was noted in ASST positive patients while size,
number of weals and intensity was similar in ASST positive and ASST
negative patients89. Sabroe et al in his study also noted significant
difference in itching on a scale of 0-10, between histamine releasing
(mean=9.5) and non histamine releasing (mean=8.0) patients40. Whereas
our study results was not comparable with the study by Bajaj et al in which
no  significant  difference  was  noted  in  pruritus  and  AHT  use  was  noted
between two groups5.
Duration of weals
In our study in the ASST positive group around 28% of patients had
score 3 and 32% had score 2. Percentage of patients having severe score
was higher in ASST positive group while majority of ASST negative(54%)
group had score 1. The difference was statistically significant (P=0.0015).
Whereas no difference in the duration of weals was noted in studies by
Bajaj et al and Staubach et al5,89. Duration of weals score was not included
in the severity grading in studies by Toubi et al, Vohra et al and De Swerdt
et al119,117,120. Further comparative clinical studies including duration of
weals in the future are needed to compare the difference in the duration of
weals between two groups.
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Size of weals
In our study majority of ASST positive patients(64%) and ASST
negative patients(50%) had score 2. There was no statistical significance
between two groups in the weal size score (P=0.0623).  Similar results
with no difference in size of weals was noted in studies conducted by Bajaj
et al and Staubach et al5,89.
Total Severity Score
There was significant difference in the TSS between both groups in
our  study.  Majority  of  ASST  positive  patients  had  severe  TSS  while
majority  of   ASST   negative   patients   had   moderate  TSS  score.
Percentage of patients having mild TSS was higher in ASST negative than
ASST positive group.
Study by Bajaj et al with similar scoring system, as used in our study
showed no significant difference in mean TSS between two groups5. But
highly significant difference in the mean TSS was noted in our study with
ASST positive patients having higher mean TSS indicating more severe
disease in them. Different types of scoring system was used in various
studies to calculate the severity of urticaria and to compare the difference
in ASST positive and negative groups.
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Sabroe et al in their study used number of weals, itching, systemic
symptoms and weal distribution to calculate total severity score. Results
obtained in their study was , patients with histamine releasing activity had
more severe score than patients with no histamine releasing activity. The
difference was statistically significant40.
Study by Vohra et al also noted significantly higher urticaria activity
score (UAS) in ASST positive patients than ASST negative patients. The
study used pruritus score and weal score to calculate the UAS117.
The difference in the significance/insignificance noted in difference
studies may be due to the different parameters used and lack of uniformity.
This denotes the need for standardization in the parameters used in
urticaria for the calculation of total severity scores.
Autologous serum therapy
The mean base line TSS value of 44 treatment completed patient
was 13.68 and at end of treatment it was 3.68. Follow up mean TSS of 41
patients was 3.98. There was significant reduction in mean TSS on
comparing base line with end of treatment (p value <0.001) and base line
with follow up (p value <0.0001).
Though there was increase in actual TSS score in some patients
during follow up, it did not reach the base line value and the difference in
the mean TSS value at end of treatment and follow up was insignificant.
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Only few studies with autologous serum therapy on chronic urticaria
patients are available. Staubach et al used autologous whole blood for
therapy. Treatment was given using autologous whole blood weekly for
eight weeks. They found significant reduction in severity scores in ASST
positive patients (41%). ASST negative patients showed only 21%
decrease in severity scores which was not different from placebo group89.
Bajaj et al in his study used autologous serum for therapy instead of
whole blood. The reason being, presence of autoreactive components in the
serum but not in the cellular components of blood, serum can be injected
using finer needles which increases compliance and immediate injection of
whole blood before it clots requires increased patient co-operation. They
noted AST was also effective in ASST negative patients.  But ASST
positive patients had dramatic decline in the severity score and lower TSS
score at follow up compared to ASST negative group. AST was given
weekly once for nine weeks and patients were followed for 12-16 weeks5.
Our study had similar duration of therapy and follow up period, but mild
increase in the mean TSS was noted in follow up. Whereas Bajaj et al
noted further decline in mean TSS during follow up. But they also noted
relapse in 2 of their patients during 12 and 18 months(more than their
study follow up period). Variation in the relapse rate during follow up in
our study compared with their study may be due to the smaller sample size
in our study.
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Since only limited studies are conducted on chronic urticaria
patients using autologous serum/ autologous whole blood for therapy, large
scale placebo controlled randomized studies with longer follow up period
are needed to know the efficacy.
Limitations:
ASST positivity is only suggestive but not diagnostic of
autoimmune urticaria. Due to the unavailability of basophil histamine
release assay which is currently the gold standard test for detection of
autoimmune urticaria, we used ASST which has a sensitivity of 70% and
specificity  of  80%.  Since  ASST positive  patients  in  our  study  had  severe
disease, AST efficacy was evaluated without a placebo control which is the
main limitation of our study.
Conclusion
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CONCLUSION
1. Prevalence of autoimmune urticaria among patients with chronic
idiopathic urticaria was 23.5%.
2. There was no difference in the epidemiological parameters like age
and sex between ASST positive and ASST negative patients.
3. No difference in the duration of the disease was noted between
ASST positive and ASST negative patients.
4. There was no significant difference in the association of atopy with
ASST results.
5. Increased association with angiodema was noted in ASST positive
patients compared to ASST negative patients.
6. ASST positive patients had more frequent episodes, severe pruritus,
prolonged duration of weals, increased requirement for
antihistamines and severe total severity score compared to ASST
negative patients.
7. No significant difference was noted in the number of weals and size
of weals between ASST positive and ASST negative patients.
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8. AST was effective in complete clearance of disease in 20%  patients.
In the remaining, it was effective in considerably reducing the total
severity of the disease.
9. 89 % of patients with complete clearance of the disease at the end of
the treatment, remained clear during follow up also.
10.Mild increase in the mean severity score during follow up was noted
compared to the mean severity score at the end of treatment. But the
increase was statistically insignificant and none of the patients
reached their initial base line score.
           ASST is a simple, cost effective, easy to perform screening test
which  can  be  done  as  an  outpatient  procedure.  It  helps  to  identify
autoimmune etiology, in patients previously categorized as having chronic
idiopathic urticaria. It also provides evidence for the rationale use of
immunomodulators in these patients.
           In patients with chronic autoimmune urticaria, AST is a cheap, cost
effective and potentially curative modality of treatment with no side
effects. Especially in those patients with severe intensity who often require
steroids and immunomodulators which are well known for their adverse
effects on long term use, AST emerges to be a better therapeutic option.
Annexures
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Proforma
PROFORMA
Name:                                   Age:              Sex:                    Occupation:
O.P No:
Address:       Phone No:
PRESENTING COMPLAINTS:
H/O PRESENTING ILLNESS:
H/O total duration of illness:
H/O itching:
H/O frequency of episodes:
H/O number of weals:
H/O pain:
H/O duration of weals:
H/O frequency of AHT use:
H/O size of weal:
H/S/O atopy:
H/O angiodema:
H/S/O respiratory tract infections:
(Sinusitis/headache/sore throat)
H/O any aggravating foods:
H/S/O gastritis:
H/O drug intake:
H/O allergy to house dust/pollen/animal danders:
H/O episodes following exposure to cold/heat/pressure/sunlight:
H/O premenstrual exacerbation:
H/O weals following exercise:
H/O thyroid problem:
H/O dental/ortho implants:
H/O breathing difficulties/difficulty in swallowing during episodes:
H/S/O any recent illness:
PAST HISTORY:
H/O diabetes/hypertension/tuberculosis/bronchial asthma.
PERSONAL HISTORY:
Diet:
Alcoholism:
Smoking:
FAMILY HISTORY:
H/O atopy
H/O autoimmune diseases:
MENSTRUAL HISTORY:
TREATMENT HISTORY:
GENERAL EXAMINATION:
Built:
Nourishment:
Anemia/jaundice/clubbing/pedal edema/dyspnoea/lymphadenopathy
BP:                                  Pulse:                         Resp rate:
CVS:
Respiratory system:
Abdominal examination:
CNS:
Endocrine system:
DERMATOLOGICAL EXAMINATION:
Description and extent of lesions:
Palms and soles:
Mucosa:
Hair:
Nails:
OPINION:
ENT
Dental to rule out focal sepsis
INVESTIGATIONS:
Complete blood count
Hb:
Total count:
Differential count:
ESR:
Urine routine:
Liver function test:
Renal function test:
Stool examination:
Thyroid function tests (if required):
USG abdomen (if required):
Master chart
MASTER CHART
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1 20 F 6 Mn 2 3 1 2 2 2 P P 12 N - - -
2 50 F 10 Y 3 3 3 2 3 2 A P 16 P 16 4 2
3 71 M 3 Mn 1 1 3 2 2 3 A A 12 N - - -
4 52 M 8 Mn 3 2 3 2 3 3 A A 16 P 16 0 0
5 20 F 6 Mn 1 2 2 3 1 3 P A 12 N - - -
6 53 M 3 Y 3 2 2 3 3 3 P P 16 N - - -
7 18 M 6 Mn 1 1 2 2 1 3 A A 10 N - - -
8 34 F 1 Y 2 2 2 1 2 2 A A 11 N - - -
9 30 F 2 Y 3 2 2 1 3 1 A P 12 N - - -
10 23 F 2 Mn 1 3 1 1 1 2 P A 9 N - - -
11 19 F 3 Mn 1 3 1 1 1 2 A P 9 N - - -
12 32 M 2 Mn 2 1 1 1 2 1 P P 8 P 8 3 3
13 22 M 2 Mn 2 2 3 2 2 1 A P 12 N - - -
14 30 F 3 Y 2 3 2 2 2 1 A A 12 N - - -
15 33 F 3 Mn 1 3 1 1 1 2 A A 9 N - - -
16 45 F 3 Mn 2 2 2 2 1 2 P P 11 N - - -
17 37 F 2 Y 3 2 1 2 3 3 A A 14 N - - -
18 35 M 13 Y 3 3 3 3 3 2 A A 17 P 17 6 6
19 36 F 3 Mn 2 2 2 1 3 2 A P 12 P 12 3 3
20 40 M 3 Y 1 2 2 2 1 2 A A 10 N - - -
21 21 F 3 Y 1 3 1 1 1 2 P P 9 N - - -
22 55 F 6 Mn 1 3 1 1 1 2 A A 9 N - - -
23 68 M 5 Y 3 3 2 2 3 2 A P 15 P 15 3 3
24 38 F 7 Y 1 3 2 2 1 2 P A 11 N - - -
25 24 F 1Y 1 3 1 1 1 2 A P 9 N - - -
26 30 F 4 Y 1 2 2 1 1 2 A P 9 N - - -
27 27 M 3 Mn 1 3 1 1 1 2 A A 9 N - - -
28 19 M 10 Y 3 3 3 3 3 2 P P 17 P 17 5 7
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29 35 F 2 Y 1 2 2 2 1 2 A A 10 N - - -
30 50 F 6 Mn 3 3 3 3 3 2 A P 17 N - - -
31 29 M 15 Y 1 2 1 1 1 2 A A 8 N - - -
32 31 F 4 Y 2 3 2 2 2 1 P A 12 N - - -
33 29 F 2 Y 1 2 1 1 1 1 A P 7 N - - -
34 70 M 6 Mn 2 2 3 1 2 2 P A 12 P 12 6 4
35 31 M 2 Y 3 2 3 3 3 3 A P 17 P 17 2 3
36 37 M 10 Y 1 2 2 2 1 2 P P 10 N - - -
37 48 F 10 Y 1 2 1 1 1 3 A A 9 N - - -
38 34 F 2 Mn 3 1 2 2 2 2 A P 12 N - - -
39 15 F 5 Mn 3 3 3 1 2 3 A A 15 P 15 - -
40 35 F 3 Mn 1 2 2 1 1 2 A A 9 N - - -
41 21 M 1 Y 2 2 2 1 1 2 P A 10 P 10 0 3
42 50 F 3 Mn 2 3 2 3 1 1 A A 12 N - - -
43 28 M 6 Mn 1 1 1 1 0 1 A A 5 N - - -
44 38 F 4 Y 3 2 3 2 3 2 A P 15 P 15 2 3
45 24 M 1.5 Y 1 3 2 1 1 1 A A 9 N - - -
46 20 M 3 Y 2 3 2 2 2 3 A A 14 N - - -
47 54 F 5 Mn 3 2 2 1 3 1 A P 12 P 12 3 2
48 30 M 4 Y 3 3 3 2 3 3 P P 17 P 17 3 4
49 27 M 4 Mn 1 3 1 1 1 1 P P 8 N - - -
50 27 F 1.5 Y 2 2 2 2 1 1 A A 10 N - - -
51 40 F 8 Mn 3 3 3 2 2 3 A A 16 N - - -
52 55 F 2 Mn 1 2 1 1 0 1 A A 6 N - - -
53 24 F 3 Mn 3 3 2 2 2 3 P P 15 N - - -
54 27 M 4 Mn 2 2 2 3 1 2 P P 12 P 12 6 6
55 19 M 8 Mn 1 1 1 1 0 1 P A 5 N - - -
56 30 M 1 Y 3 2 2 1 2 2 A P 12 N - - -
57 36 F 4 Mn 1 3 1 1 1 2 A A 9 N - - -
58 50 F 1 Y 3 2 2 3 3 2 P A 15 P 15 0 0
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59 33 M 3 Mn 1 1 1 1 0 1 A A 5 N - - -
60 57 F 1 Y 2 3 2 3 1 1 P A 12 N - - -
61 32 M 1.5 Mn 1 1 2 2 1 2 A P 9 N - - -
62 33 F 5 Mn 3 2 3 2 3 3 A A 16 N - - -
63 19 M 2 Y 3 3 3 3 3 3 P P 18 N - - -
64 20 M 1 Y 2 2 2 2 2 2 A P 12 P 12 6 6
65 67 F 1 Y 2 2 1 3 1 1 A A 10 N - - -
66 66 F 3 Y 1 2 1 2 1 1 A P 8 N - - -
67 63 M 5 Mn 1 3 1 1 1 2 A A 9 N - - -
68 38 F 6 Mn 1 2 1 1 0 1 A A 6 N - - -
69 22 F 3 Y 3 3 3 3 3 2 P P 17 N - - -
70 65 F 3 Mn 1 3 1 1 1 1 A A 8 N - - -
71 53 M 3 Y 2 3 2 2 3 2 P A 14 N - - -
72 65 F 3 Mn 2 3 3 2 1 1 A A 12 N - - -
73 36 F 1 Y 3 2 2 2 3 2 A P 14 N - - -
74 35 F 5 Mn 3 3 3 3 3 3 A P 18 P 18 6 7
75 35 F 2 Mn 1 3 1 1 1 1 P P 8 N - - -
76 55 F 2 Mn 1 1 1 1 0 1 A A 5 N - - -
77 33 M 1.5 Y 2 2 2 2 2 3 P P 13 N - - -
78 40 M 6 Mn 2 2 3 2 2 3 A A 14 N - - -
79 22 F 6 Mn 2 3 2 2 2 3 A A 14 N - - -
80 45 F 1.5 Y 3 3 2 2 3 1 A A 14 P 14 3 6
81 23 M 3 Mn 1 3 1 1 1 1 A P 8 N - - -
82 28 M 2 Y 1 3 1 1 1 1 A A 8 N - - -
83 18 M 6 Mn 3 2 2 3 3 2 P P 15 N - - -
84 26 F 3 Y 3 3 2 2 3 2 A A 15 N - - -
85 40 M 2 Mn 1 3 1 1 1 1 P A 8 N - - -
86 59 M 3 Mn 3 3 2 1 3 3 A P 15 P 15 3 3
87 27 F 2 Mn 3 2 2 1 3 1 P A 12 P 12 3 3
88 36 M 6 Y 1 2 2 1 1 2 P A 9 N - - -
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89 16 M 3 Mn 1 3 3 1 1 1 A A 10 N - - -
90 40 F 3 Mn 3 2 2 1 3 1 P A 12 N - - -
91 24 M 2 Mn 1 3 3 1 1 1 A P 10 N - - -
92 28 M 3 Mn 1 3 1 1 1 1 A A 8 N - - -
93 41 F 2 Y 2 2 1 3 2 2 P P 12 N - - -
94 67 M 12 Y 3 2 2 2 2 2 A P 13 N - - -
95 18 M 3 Y 1 1 1 1 1 1 A A 6 N - - -
96 30 M 10 Y 2 3 2 1 1 1 P P 10 N - - -
97 50 F 3 Mn 1 1 1 1 1 1 A A 6 N - - -
98 40 F 6 Mn 3 3 3 2 3 2 P P 16 P 16 6 8
99 50 F 6 Mn 3 2 2 1 2 1 A A 11 N - - -
100 32 F 3 Y 2 3 2 2 1 2 P A 12 N - - -
101 56 F 2 Y 1 2 1 1 1 2 A A 8 N - - -
102 45 M 1 Y 1 3 3 1 1 1 A P 10 N - - -
103 18 F 1 Y 3 2 1 1 3 1 A A 11 P 11 3 4
104 40 F 7 Mn 3 2 1 1 3 2 A A 12 N - - -
105 21 M 1 Y 3 3 2 2 3 2 A P 15 P 15 - -
106 26 F 1 Y 3 2 2 1 2 2 A A 12 N - - -
107 45 F 1 Y 1 1 1 1 0 1 A A 5 N - - -
108 50 F 2 Mn 1 3 1 1 1 2 P P 9 N - - -
109 23 F 4 Mn 2 3 2 2 1 1 A A 11 N - - -
110 13 F 4 Mn 2 3 2 2 2 1 A A 12 N - - -
111 30 F 2 Mn 3 3 2 2 2 2 P P 14 N - - -
112 45 F 2 Y 2 2 3 1 1 2 P A 11 N - - -
113 40 F 8 Mn 3 2 2 1 2 2 A P 12 N - - -
114 18 F 1 Y 2 2 2 1 2 1 P A 10 P 10 5 3
115 29 M 3 Y 2 2 3 2 1 2 A A 12 N - - -
116 25 M 2 Mn 1 2 1 1 0 1 A A 6 N - - -
117 42 F 10 Y 1 3 3 1 1 1 P P 10 N - - -
118 32 M 3 Mn 2 3 3 2 1 1 A A 12 N - - -
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119 28 F 5 Mn 2 2 3 2 1 2 A A 12 N - - -
120 43 F 1 Y 1 3 3 1 1 1 P P 10 N - - -
121 50 M 10 Y 3 3 3 3 3 2 A P 17 P 17 0 0
122 23 M 2 Y 3 3 3 2 3 2 A P 16 P 16 0 0
123 54 F 4 Y 3 2 2 3 3 2 A P 15 P 15 6 6
124 38 F 3 Y 2 2 2 2 2 2 P P 12 P 12 4 0
125 26 F 5 Y 2 3 2 1 2 2 A P 12 P 12 3 3
126 43 F 10 Y 3 3 3 3 3 2 A P 17 P 17 8 8
127 52 F 8 Y 3 3 2 2 3 2 A A 15 P 15 10 13
128 25 F 3 Mn 2 2 2 2 2 2 P A 12 N - - -
129 25 M 8 Mn 3 2 2 1 2 2 P P 12 N - - -
130 30 M 1 Y 3 2 3 2 3 2 A A 15 N - - -
131 19 F 5 Mn 1 2 1 1 0 1 A A 6 N - - -
132 24 M 9 Mn 1 3 3 1 1 3 P A 12 N - - -
133 34 M 2 Y 2 3 2 2 1 2 P P 12 N - - -
134 33 M 3 Mn 3 2 1 1 3 1 A A 11 P 11 3 3
135 31 F 4 Mn 2 3 2 1 1 1 A A 10 N - - -
136 47 M 3 Mn 2 2 2 1 2 2 P P 11 P 11 6 8
137 55 F 4 Mn 1 1 1 1 1 1 A P 6 P 6 0 0
138 30 M 2 Y 3 2 2 2 2 2 A A 13 N - - -
139 40 M 3 Y 2 2 2 1 1 2 A A 10 N - - -
140 37 F 6 Mn 2 2 2 1 2 2 A P 11 N - - -
141 40 F 2 Mn 1 3 3 1 1 1 A A 10 N - - -
142 30 F 3 Mn 2 2 3 1 2 2 A A 12 N - - -
143 16 F 4 Mn 3 2 2 1 3 2 A A 13 N - - -
144 27 F 3 Y 2 2 2 2 2 2 A A 12 N - - -
145 29 F 7 Mn 2 1 1 1 2 1 A A 8 P 8 3 3
146 55 M 3 Y 3 3 3 2 3 2 A A 16 N - - -
147 40 F 3 Mn 2 2 3 1 1 2 P P 11 N - - -
148 42 M 1 Y 2 2 2 2 2 2 P A 12 N - - -
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149 50 F 2 Mn 1 2 1 1 0 1 A P 6 N - - -
150 30 M 6 Mn 2 2 3 2 1 2 A A 12 N - - -
151 43 F 4 Mn 2 2 2 2 2 1 P P 11 N - - -
152 50 M 2 Mn 2 3 2 1 1 2 A A 11 N - - -
153 30 F 4 Y 1 1 1 1 1 1 A A 6 N - - -
154 45 F 1 Y 1 2 1 1 0 1 A A 6 N - - -
155 39 F 2 Mn 3 2 3 2 2 2 A A 14 N - - -
156 26 M 2 Y 3 2 2 1 3 2 A A 13 P 13 3 -
157 17 M 2 Y 2 2 2 2 2 2 A P 12 P 12 0 -
158 60 M 3 Y 3 2 2 1 3 2 A A 13 P 13 7 6
159 35 F 1 Y 3 3 3 3 2 2 A A 16 P 16 8 8
160 32 F 6 Mn 3 3 3 3 3 3 A P 18 P 18 - -
161 30 M 4 Y 2 2 3 1 2 2 A P 12 P 12 6 -
162 40 F 5 Y 3 3 3 2 3 2 A P 16 P 16 0 0
163 29 M 2 Y 2 2 2 2 2 2 P A 12 P 12 4 6
164 18 F 10 Mn 3 3 2 1 3 2 A P 14 P 14 4 4
165 24 M 3 Y 3 3 3 3 3 2 A A 17 P 17 0 0
166 56 F 10 Y 3 3 3 3 3 3 P P 18 P 18 6 6
167 32 F 1 Y 2 3 2 2 2 3 A A 14 N - - -
168 40 M 2 Y 2 2 3 1 2 2 A A 12 N - - -
169 28 M 11 Mn 2 2 2 1 1 2 A A 10 N - - -
170 40 M 2 Y 3 3 3 3 2 3 A A 17 N - - -
171 28 F 3 Mn 1 3 3 1 1 1 P P 10 N - - -
172 28 M 1 Y 2 2 2 1 1 2 A A 10 N - - -
173 23 F 3 Mn 1 3 3 1 1 1 A A 10 N - - -
174 40 F 8 Mn 2 3 2 2 1 2 A P 12 N - - -
175 16 F 1 Y 3 3 2 2 2 2 A A 14 N - - -
176 55 F 2 Y 3 3 3 3 2 2 P P 16 N - - -
177 38 M 5 Y 2 2 3 1 2 2 A A 12 N - - -
178 27 M 2 Mn 2 2 3 2 2 2 A A 13 N - - -
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179 29 F 8 Mn 2 2 2 1 2 1 A A 10 N - - -
180 32 M 3 Mn 1 3 3 1 1 1 A A 10 N - - -
181 35 F 6 Mn 1 3 3 1 1 1 P P 10 N - - -
182 24 F 1 Y 2 2 2 1 1 3 A A 11 N - - -
183 19 F 1 Y 2 3 3 2 2 2 A P 14 N - - -
184 51 M 2 Mn 1 3 3 1 1 1 A A 10 N - - -
185 28 M 6 Mn 2 2 1 2 1 2 A A 10 N - - -
186 46 F 1.5 Y 2 2 1 1 1 2 A P 9 N - - -
187 15 M 2 Y 2 2 3 1 2 1 A P 11 N - - -
188 40 M 3 Y 1 3 3 1 1 1 A A 10 N - - -
189 46 F 4 Mn 3 2 2 2 2 2 A A 13 N - - -
190 32 F 7 Mn 1 2 3 2 1 3 P A 12 N - - -
191 38 M 6 Y 2 2 2 2 1 2 A P 11 N - - -
192 51 M 10 Y 3 3 3 2 3 2 A A 16 N - - -
193 49 F 1 Y 3 3 2 2 2 2 A A 14 N - - -
194 21 F 3 Mn 2 2 2 2 1 2 A A 11 N - - -
195 26 F 2 Mn 1 3 3 1 1 1 A P 10 N - - -
196 36 M 10 Mn 2 3 2 1 2 2 A A 12 N - - -
197 26 M 1 Y 1 2 1 1 0 1 A A 6 N - - -
198 37 F 2 Y 2 2 2 2 2 2 A A 12 N - - -
199 44 M 3 Y 2 3 3 2 1 1 P A 12 N - - -
200 56 F 1 Y 1 2 1 1 0 1 A P 6 N - - -
KEY TO MASTER CHART
A –  Absent
F –  Female
M –  Male
Mn –  Month
P –  Present
S.NO –  Serial Number
TSS –  Total Severity Score
Y –  Year
Abbreviations
ABBREVIATIONS
AHT –  Antihistamines
APST –  Autologous Plasma Skin Test
APC –  Antigen Presenting Cell
ASST –  Autologous Serum Skin Test
AST –  Autologous Serum Therapy
CIU –  Chronic Idiopathic Urticaria
CNS  –  Central Nervous System
CVS –  Cardio Vascular System
ELISA  –  Enzyme Linked Immuno Sorbent Assay
ESR –  Erythrocyte Sedimentation Rate
GM  CSF  –  Granulocyte Monocyte Colony Stimulating Factor
HLA –  Human Leucocyte Antigen
HRF –  Histamine Releasing Factor
ICAM –  Intercellular Adhesion Molecule
IgE –  Immunoglobulin E
IgG –  Immunoglobulin G
INF –  Interferon
IVIG –  Intravenous Immunoglobulin
LT –  Leucotriene
mRNA –  Messenger RNA
NSAID  –  Non Steroidal Anti Inflammatory Drugs
PT INR  –  Pro Thrombin International Normalized Range
PUVA –  Psoralein Ultra Violet A
RPM –  Rotations Per Minute
TSS –  Total Severity Score
UAS –  Urticarial Severity Score
USG –  Ultra Sonogram
VCAM  –  Vascular Cell Adhesion Molecule

